Table 2.
Pathologic and clinical outcomes.
| Variable | |
|---|---|
| Median fluvastatin duration, days (range) | 49 (27–102) |
| Median compliance, % (range) | 99% (78–100%) |
| Pathologic stage, n (%) | |
| pT0 | 0 (0%) |
| pT1 | 0 (0%) |
| pT2 | 16 (48%) |
| pT3 | 17 (52%) |
| pT4 | 0 (0%) |
| Extraprostatic extension, n (%) | 15 (45%) |
| Positive margins, n (%) | 9 (27%) |
| Positive nodes, n (%) | |
| pN0 | 20 (61%) |
| pN1 | 2 (6%) |
| pNX | 11 (33%) |
| RP Gleason score, n (%) | |
| 5 (2 + 3 or 3 + 2) | 3 (9%) |
| 6 (3 + 3) | 4 (12%) |
| 7 (3 + 4) | 22 (67%) |
| 7 (4 + 3) | 3 (9%) |
| 8 (4 + 4) | 1 (3%) |
| Change from baseline Gleason score, n (%) | |
| Upgraded | 1 (3%) |
| No change | 26 (79%) |
| Downgraded | 6 (18%) |
| Median follow-up, months (range) | 36 (8–52) |
| BCR and/or use of RT and/or ADT, n (%) | |
| BCRa | 6 (18%) |
| Salvage RT | 6 (18%) |
| Adjuvant RT | 2 (6%) |
| ADT | 3 (9%) |
| Metastatic CRPC, n (%) | 1 (3%) |
CRPC castration-resistant PCa.
aBCR = two consecutive PSA values above 0.2 ng/mL, receipt of salvage radiation therapy (RT) and/or receipt of androgen deprivation therapy (ADT).